For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231129:nRSc9864Ua&default-theme=true
RNS Number : 9864U Benchmark Holdings PLC 29 November 2023
29 November 2023
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Full Year Results for the Financial Year ended 30 September 2023
Third consecutive year of financial and strategic delivery
Strategic steps to further streamline and integrate the Group, positioning it
for the next phase of growth
Benchmark, the aquaculture biotechnology company, announces its full year
audited results for the year ended 30 September 2023 (the "period").
Financial highlights - Revenue growth and improved profitability with steady
progress in all business areas
· Revenue from continuing operations increase of 7% (+7% CER**):
o Advanced Nutrition - strong performance in challenging shrimp markets,
further strengthening our leading market position; revenues -2% (-7% CER)
o Genetics - strong performance with record salmon egg sales in our three
facilities - Iceland, Norway and Chile; revenue growth of +14% (+20% CER)
o Health - growing adoption of sea lice solution Ectosan® Vet and
CleanTreat® and increase in sales of Salmosan® Vet resulting in revenue
growth of 27% (+29% CER)
· 15% increase (+16% CER) in Adjusted EBITDA from continuing
operations, excluding fair value movements from biological assets, as a result
of higher revenues and tight cost control
· Adjusted EBITDA(1) margin from continuing operations excluding fair
value uplift from biological assets increased to 21% (FY22: 20%)
· Significant progress towards profitability:
o Adjusted operating profit from continuing operations increased by 36% to
£14.6m (FY22: £10.7m)
o Loss before tax from continuing operations reduced to £12.7m (FY22
restated: £21.4m) due to the positive trading result and lower finance costs,
partially offset by higher exceptional items
· Significant improvement in cash generation with operational cash flow
close to double to £20m (FY22: £10.8m); cash conversion(4) increased from
35% to 58%
· Net debt(3) reduced to £65.5m (FY22: £73.7m)
· Cash and cash equivalents of £35.6m and available liquidity of
£48.8m
· At 27 November, cash and cash equivalents of £29.3m and available
liquidity of £41.5m
£m FY 2023 FY 2022 % AER % CER**
restated*
Revenue from continuing operations 169.5 157.7 7% 7%
Adjusted
Adjusted EBITDA(1) from continuing operations 35.5 32.6 9% 11%
Adjusted EBITDA from continuing operations excluding fair value uplift from 35.6 31.0 15% 16%
biological assets
Adjusted operating profit(2) from continuing operations 14.6 10.7 36% 41%
Statutory
Operating loss from continuing operations (5.3) (6.2) 15% 22%
Loss before tax from continuing operations (12.7) (21.4) 41% 44%
Loss for the period including discontinued operations (21.6) (30.5) 29% 31%
Basic loss per share (p) (3.16) (4.60) 31%
Net debt(3) (65.5) (73.7)
Net debt excluding lease liabilities (45.6) (47.5)
* 2022 figures have been restated to reflect changes to the ongoing continuing
business during the year following the disposal of the tilapia business
** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related items.
(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
(4) Cash generated from operations after working capital and taxes as
percentage of Adj. EBITDA
Business Area Performance (continuing operations) FY 2023 FY 2022 % AER % CER**
£m restated *
Revenue
Genetics 65.5 57.4 14% 20%
Advanced Nutrition 78.5 80.3 (2%) (7%)
Animal Health 25.5 20.1 27% 29%
Adjusted EBITDA(1)
Genetics 15.7 17.4 (10%) (1%)
- excluding fair value movements in biological assets 15.8 15.8 0% 8%
Advanced Nutrition 18.4 19.0 (3%) (8%)
Animal Health 4.8 0.1 4,295% 4,165%
** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.
Operational highlights
Advanced Nutrition - commercial focus and programme of efficiencies translate
into business resilience and stronger market position
· Continued commercial focus leveraging technical services capabilities
and adapting to market conditions
· Commenced implementation of structured programme of operational
efficiencies focused on automation, supply chain integration, and digitalised
data management
· Continued innovation with launch of first AI-enabled live feed
counting tool SnappArt and establishment of new R&D collaborations in
Ecuador and Singapore
Genetics - continue to strengthen global position in salmon eggs
· Record volume of salmon eggs of 335 million, a 15% increase
· Acquired remaining 10.52% minority interest in Benchmark Genetics
Iceland (50% of Group's salmon egg production) for €9m
· Doubling of sales demonstrate growing commercial traction in Chile
where our facilities obtained disease-free compartment status enabling future
exports
· Development of a new shrimp genetics product portfolio underway;
shrimp activities reorganised and aligned to realise synergies with Advanced
Nutrition
· Divestment of tilapia business through an MBO
· Expanded R&D team with a focus on reproductive technologies
paving the way for breakthrough developments in sterility and gene editing
Health - increased adoption of Ectosan® Vet and CleanTreat®
· Increased adoption of Ectosan® Vet and CleanTreat® by large and
small producers along the entire Norwegian coastline
· Further progress in the development of a new business model and
configuration for CleanTreat® to integrate the system into customers'
wellboat infrastructure
· Good year for our second sea lice treatment, Salmosan® Vet, which
showed a resurgence of demand driven mainly by label changes which allow
longer use in certain territories
Group - further streamlining and integration creating opportunities for
commercial and cost synergies
· Important strategic alignment bringing together our salmon
activities under the leadership of our Head of Genetics and our shrimp
activities under the leadership of our Head of Advanced Nutrition. This
customer-centric structure will enable us to increase our commercial impact
with a combined offering and customer network and realise synergies
· Continued progress on sustainability initiatives including energy
efficiency and GHG emissions, certification and development of novel feed
ingredients. ESG rating improvement by MSCI to AA
· Looking forward the Group remains focused on its four strategic
pillars:
o Maintain and grow its leadership position in established markets
o Expand its business through the launch of new products and development of
key growth vectors
o Continue to embed the "One Benchmark" culture and integrate the Group to
realise synergies
o Pursue strategic opportunities adhering to strict criteria
Current trading and outlook - positive momentum trading in-line with
management expectations
· Good start to FY24 and positive momentum in the business
o Good visibility of revenues in salmon genetics
o Early indications of improvement in the shrimp markets
o Increase in sea lice treatments post period end with good capacity
utilisation of CleanTreat®; expect normal seasonality
Trond Williksen, CEO, commented:
"We delivered good growth in revenue and Adjusted EBITDA, and increased cash
conversion, despite challenging conditions in the global shrimp markets. This
demonstrates the strength of our business and the agility of our organisation
to adapt - mitigating the impact of a soft market and taking advantage of
commercial opportunities to further consolidate our leading market position.
The new financial year has also started well and in line with our
expectations, with positive momentum in our three business areas.
"Since the end of FY20 when we completed the Group restructuring, we have been
building a track record of growth and improved profitability, reflected by
revenues and Adjusted EBITDA from continuing operations which have increased
over this period by 61% and 128%, respectively.
"Benchmark is uniquely positioned in an industry that is structurally growing
supported by attractive megatrends. With a clear strategy and an integrated
commercial network covering the main aquaculture species, we have significant
opportunity to deliver growth and shareholders returns. We will continue the
execution of our strategy to realise the value inherent in our business for
the benefit of all our stakeholders."
Presentation for analysts and institutional investors at 8am GMT
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 GMT (09.00 CET).
The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)
A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20231129_1
(https://protect-eu.mimecast.com/s/15WXC98RjU4AznQtoqXNf?domain=channel.royalcast.com)
Equity Development webcast for retail investors at 12pm GMT
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers at
12.00 GMT (13:00 CET). The webcast is open to all existing and potential
shareholders.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-29november2023
(https://protect-eu.mimecast.com/s/5rvkClOj0cRmzPPHGCXA2?domain=equitydevelopment.co.uk)
Enquiries
Benchmark Holdings plc Tel: 0114 240 9939
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Deutsche Numis (Broker and NOMAD) Tel: 020 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah
MHP Tel: 020 3128 8100
Katie Hunt, Reg Hoare, Veronica Farah benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark's mission is to enable aquaculture producers to improve their
sustainability and profitability. We bring together biology and technology, to
develop innovative products which improve yield, quality and animal health and
welfare for our customers. We do this by improving the genetic make-up, health
and nutrition of their stock - from broodstock and hatchery through to nursery
and grow out. Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics and sea lice
treatments. Find out more at www.benchmarkplc.com
(http://www.benchmarkplc.com)
Chairman's Statement
A year of delivery
2023 marks the third consecutive year of financial and strategic delivery
following the Group restructuring and the appointment of a new management team
in 2020. The new financial discipline and commercial focus implemented by our
CEO and CFO are now well embedded in the Group and, together with our ongoing
organisational change programme, are driving continued growth and strategic
progress. Since 2020 Benchmark's revenue from continuing operations has grown
from £105.4m (after adjusting for £0.2m revenue from the divested tilapia
business) to £169m and Adjusted EBITDA has increased from £15.5m (after
adjusting for loss of £1.1m from the divested tilapia business) to £35.5m,
turning operating cashflow positive. In the same period, operating loss has
reduced from £9.6m (after adjusting for loss of £1.2m from the divested
tilapia business) to £5.3m, and total loss for the year has reduced from
£31.9m to £21.6m.
We have a strong business with a capable organisation which is capitalising on
the attractive megatrends in our industry, and which has proven its agility to
adapt to the cyclicality in our end markets, taking every opportunity to
further consolidate our leading market position.
The structural growth drivers in our industry are increasingly compelling.
Aquaculture plays a crucial role in meeting the demand for seafood and
represents a growing proportion of seafood consumption.
In addition, there are a number of exciting trends gaining momentum which are
further driving the demand for innovative biotechnology solutions which are
our focus. For instance, the increasing adoption of certification standards;
the adoption of technological advancements, from automation to genetic
improvements; the emergence of alternative feeds; and the increased use of
data driven, AI enabled decision making are all aligned with and support
Benchmark's future growth.
Organisational transformation
We continued our strategic journey to integrate and streamline our
organisation in order to realise synergies, reduce costs and enhance our
customer value proposition. This is an effort that commenced three years ago
and crystallised this year with the integration of our Health, Genetics and
Advanced Nutrition salmon and shrimp offerings by species in order to drive
greater synergies into those end markets.
This means we can now fully leverage our customer relationships and commercial
footprint to cross-sell our offerings and develop new products and solutions.
Our salmon and shrimp activities are now respectively led by Geir Olav
Melingen and Patrick Waty, both strong commercial leaders, who also continue
to be business area heads for Genetics and Advanced Nutrition. As a result of
the change we were able to streamline the teams with immediate cost savings.
Listing venue and share price performance
It is evident to the Board that our share price does not reflect the
fundamental value of the business, its growing track record, or unique
strategic positioning and attractive prospects. In an effort to address this
longstanding issue, the Board decided to pursue a listing in Oslo, the leading
seafood market in order to attract specialist investors and over time attain a
fair valuation for our shares. An initial listing on Euronext Growth Oslo
announced in November 2022 represented a first step towards this goal, to be
followed by an uplisting to the Oslo Børs, subject to shareholder approval.
In 2023, we conducted a consultation with shareholders regarding an uplisting
to the Oslo Børs and simultaneous delisting from AIM. However, we concluded
from these discussions that it was necessary to maintain listings on both
Euronext Growth Oslo and on AIM for the foreseeable future and keep an
uplisting under review as part of the Group's ongoing strategy to deliver
shareholder value.
Board changes
During the year we made changes to the Board that increased shareholder
representation, improved the gender
balance, and addressed the normal Board rotation cycle.
In December we appointed Laura Lavers as Non-Executive Director. Laura is an
experienced investment professional with two decades of experience and acts as
shareholder representative for JNE Partners, a significant shareholder in the
Company. In April, we announced the appointment of Torgeir Svae as Non-
Executive Director with Atle Eide stepping down at the same time. Torgeir is
an Investment Director at Kverva AS, one of the Company's main shareholders,
and acts as their shareholder representative.
Following the appointments of Mrs Lavers and Mr Svae, alongside our
independent directors, we have three Non-Executive Directors representing our
three main shareholders who collectively hold 71% of the Company's shares.
As a step to enhance Board diversity in the normal rotation of Directors, on
30 June we appointed Marie Danielsson as Non-Executive Director and Chair of
the Audit Committee succeeding Kevin Quinn who joined the Board in 2016.
In December 2023, Susan Searle, the Company's most tenured Board member, will
conclude her service on the Board. The Board wishes to express its heartfelt
gratitude for her exceptional contributions and dedicated work over the past
decade.
Sustainability
Sustainability is at the core of our mission and our sustainability strategy
runs across all our business and extends to our supply chain; it guides our
decision-making and investment strategy. Our sustainability report including
in the group's Annual Report for the year ended 30 September 2023 sets out the
initiatives the progress made during the year in our three Sustainability
pillars: Environment, Animal Welfare and People and Communities. We set
priorities for our three pillars in alignment with a materiality assessment
carried out annually which reflects key areas of impact for the business and
our stakeholders. This year areas of focus included certification of our
operations, sustainability of our supply chain, and enhanced climate risk
assessment reporting.
Through enhanced disclosure and policies we were pleased to achieve an
improvement in our MSCI ESG ratings to AA.
We have an ambitious commitment to energy transition. In 2023, we made
substantial progress towards our Net Zero goals with the installation of solar
panels in our facility in Thailand which represents the majority of our GHG
emissions. The new solar panels will be operational in Q1 FY24.
Our People
Benchmark is driven by a group of highly talented and motivated people at all
levels around the world, and I thank them all on the Board's behalf for their
contribution this year. We continued to invest in making Benchmark a great
place to work through an ambitious engagement programme, new learning and
development resources, and regular, open communication with the management
team. For a third consecutive year we obtained excellent engagement scores in
our employee survey, well above the industry norm.
Looking forward
Our organisation is stronger than ever and, with market leading positions in
our three business areas, I am confident that we will continue to build on our
record of consistent delivery despite short term headwinds in some of our
markets. Our focus continues to be on creating shareholder value by building a
sustainably profitable, cash generative business positioned to capitalise on
the opportunity to deliver healthy, nutritious, sustainable food for our
future generations.
Peter George
Chairman
Chief Executive Officer's Review
Delivery and strategic progress
Third consecutive year of financial and strategic delivery
I am pleased to report a third consecutive year of financial delivery and
strategic progress at Benchmark. The change programme which we embarked on
three years ago and which is ongoing has transformed Benchmark into a robust
and commercial organisation with leading market positions focused on
delivering growth and shareholder value.
Supported by industry megatrends and growing interest in sustainability,
farming efficiency and animal welfare, Benchmark is uniquely positioned in the
aquaculture industry. With a clear focus on three business areas - Genetics,
Advanced Nutrition and Health we deliver specialised, mission critical
solutions that address the most important challenges facing the aquaculture
industry today. This creates excellent opportunities and prospects ahead for
Benchmark.
FY23 Overview
We delivered good growth in revenue and Adjusted EBITDA despite challenging
conditions in the global shrimp markets. This demonstrates the strength of our
business and the agility of our organisation to adapt - mitigating the impact
of a soft market and taking advantage of commercial opportunities to further
consolidate our leading market position. We continued to build on our
established track record of growth and improved profitability with revenues
increasing by 7%, and Adjusted EBITDA from continuing operations excluding
fair value movements from biological assets by 15%. Operating loss for the
year reduced by 15% from the previous year, and total loss for the year
reduced 29%. Since the end of FY20 when we completed the Group restructuring,
revenues and Adjusted EBITDA from continuing operations have increased by 61%
and 128%, respectively after adjusting for the divested tilapia business. In
the same period, operating loss reduced by 45% and total loss for the year
reduced by 32%.
Good performance in our core established business
Our three business areas reported good contribution and progress. Advanced
Nutrition showed the strength of an excellent organisation and was able to
land a good year despite weak shrimp markets which resulted in a drop in
demand for our products in key markets. Genetics increased revenues by 14%
driven by its core established business with record salmon egg sales from its
three facilities in Iceland, Salten and Chile, and continued to invest in its
growth vectors. Health reported 27% revenue growth. With leading market
positions, good commercial momentum, and growth in our underlying markets we
expect further organic growth in our core areas.
Innovation capability coupled with deep market insight sets us apart. During
the year we strengthened our Genetics R&D team with a focus on
reproductive technologies aiming to bring new breakthroughs in sterility and
gene editing to the market in the coming years. In Advanced Nutrition we
launched our first AI-powered artemia counting tool SnappArt, an example of
how we incorporate state of the art technology into our product offering.
Growth vectors
In addition to the growth potential across our established core business, we
have three significant growth vectors which represent strategic priorities for
the Group:
· the commercial expansion of our salmon genetics into the Chilean
market;
· the commercialisation of our shrimp genetics products; and
· the development of a new business model and operating platform for
Ectosan® Vet and CleanTreat®.
During the year we devoted considerable effort and resources to ensure that we
have a compelling customer proposition and the right infrastructure and cost
base in each of our growth vectors to deliver adequate returns.
Chile is the second largest salmon producing country in the world and a
natural new market for our salmon
genetics business. Barriers to entry in genetics are high and it is by
leveraging our world class genetics expertise to develop a pure Chilean strain
and our extensive operational capabilities that we have a competitive product
in the market which is reliable, biosecure and high performing. Results from
our first full production cycle demonstrate this, translating into new
customer wins and a growing pipeline of orders supported by an intense
commercial effort from our local and global team.
We see significant potential in shrimp genetics as a driver of growth and
sustainability in shrimp production; indeed, this is an area where Benchmark
has world class capabilities and expertise. We launched our first commercial
shrimp genetics products in 2022 exporting breeders from our production
facility in Florida to multiple markets in Asia. Based on feedback from the
first commercial phase, in FY23 we decided to develop a new range of products
addressing a need in the market for growth and balanced strains in addition to
resistance, as well as a need for locally adapted strains tailored to
variations in customer needs across countries. We undertook trials to enable
product testing in local conditions and our new product development is well
progressed. We also took the decision to exit our JV multiplication centre in
Thailand and plan to develop alternative market routes for our shrimp genetics
through partnerships with other industry players, leveraging our extensive
network and established relationships. In order to leverage our leading
market position and commercial network in the shrimp market through Advanced
Nutrition, we combined our shrimp activities across Genetics and Advanced
Nutrition under the leadership of Patrick Waty, our Head of Advanced
Nutrition.
Our sea lice solution Ectosan® Vet and CleanTreat® has proven to be highly
efficacious, protective of animal welfare and the environment, and represents
a key growth vector for Benchmark. During the year there was increased
adoption of our sea lice solution by small and large producers along the
entire Norwegian coastline. Full market penetration, however, relies on the
development of a new business model and configuration aligned to our
customers' infrastructure. During the year we signed an agreement with a
specialist wellboat equipment provider, MMC, and ship designer, SALT, to
integrate CleanTreat® systems into new wellboats.
This also opens up opportunities for retro-fits or installations on platforms
other than the current PSV (platform supply vessel) setup. The implementation
of the new business model will allow us to streamline the organisation and
reduce capital intensity. Part of these actions are reviewing different
options to optimise operations and cash flow on our journey towards fully
integrated customer-owned systems, including taking down the exposure to the
capital intensive setup we currently hold with two PSV's.
Strategic Action
We continue our efforts to integrate and streamline the Group - making sure we
have an organisation that is as optimal as possible from an operational and
commercial point of view. To this end we executed an important alignment in
the year bringing together our salmon activities under the leadership of our
Head of Genetics and our shrimp activities under the leadership of our Head of
Advanced Nutrition. This customer-centric will enable us to increase our
commercial impact with a combined offering and customer network, leveraging
resources and knowledge and further strengthening our market leading position.
Our overarching aim to achieve profitability and sustainable cash generation
led to the decision to exit from our tilapia breeding operation while
maintaining our exposure to this species through our Genetic Services
business. Having developed top performing genetics and an efficient operation
and supply chain, the slow industrialisation and adoption of tilapia genetics
in the industry meant that we did not see a path to adequate returns in the
short and medium term. We were pleased to have exited the business through a
management buyout and we continue to work with the new owners providing
support for the breeding programme through our Genetics Services activities.
Our culture and our people
Benchmark's purpose driven team and culture is our most important asset. Our
values underpin the way we conduct our business and create a collaborative,
innovative and commercial organisation which I am very proud of. We take
employee well-being and engagement seriously and create regular opportunities
to facilitate dialogue. These are an important pillar in making Benchmark a
'Great Place to Work'.
Looking forward - Outlook
We have had a good start to the year and there is good momentum in the
business. We have good visibility of sales in Genetics at normalised levels
following the supply shortage experienced Q1 FY23. In Advanced Nutrition we
are seeing early signs of recovery in the shrimp markets which we expect will
contribute positively from Q2 FY24 onwards. Our CleanTreat® units are
currently operating at a good capacity utilisation and we expect this to be
reflected in Q1 FY24. We expect normal seasonality with low treatment volumes
in the second half. We are considering actions to optimise our operations and
cashflow during the transition to an integrated customer solution. The
continued integration and streamlining of the Group will enable us to further
leverage the Group capabilities and drive efficiencies contributing to a
positive outlook for the year ahead.
Looking into the future, we are uniquely positioned in an industry that is
structurally growing. With a clear strategy addressing the main aquaculture
species, we have significant opportunity to deliver growth and shareholder
returns. We will continue the development of the Group and ongoing
consideration of our strategy to realise the value inherent in our business
for the benefit of all our stakeholders.
Trond Williksen
Chief Executive Officer
Financial Review
Strong and positive performance in the year
We continued to develop a business structured for growth and resilience. FY23
has been a year of significant progress in which we have delivered sales
growth in both Genetics and Health, our two salmon focussed business areas.
Additionally, in Advanced Nutrition, we have been able to continue to make
progress even despite difficult economic conditions in which the market
contracted. Our continued focus on cost and cash conservation has proven key
to our progress and we ended the year with healthy cash, net debt and
available liquidity position. We anticipate that the shrimp markets will
improve somewhat in FY24 and our shrimp focussed businesses are poised to
benefit. Salmon continues to be a very solid market for the Group allowing us
to continue to progress the business in line with our strategic objective to
be the preferred supplier of salmon eggs in all key markets.
Overview of reported financial results During 2023, the Group's focus was on
continuing to strengthen the business and deliver good commercial results and
advancing its strategic priorities with the aim to be cash generative.
Advanced Nutrition continued to deliver strong results even as they faced
headwinds in the shrimp markets demonstrating good resilience within the
business area. Genetics had a good year with strong sales and solid results,
and with Ectosan® Vet and CleanTreat® sales gaining more traction in Health
this resulted in an increase in Group revenue of 7% to £169.5m in the year
(2022 restated: £157.7m). This increase in sales meant that gross profit
increased to £86.8m (2022 restated: £83.9m). Gross margin was slightly down
at 51% (2022 restated: 53%). Using the same foreign exchange rates experienced
in 2022 (constant currency⁵) revenue increased by 7%.
2022
As Reported (£m unless otherwise stated) 2023 restated* % AER % CER(**)
Revenue from continuing operations 169.5 157.7 7% 7%
Operating loss from continuing operations (5.3) (6.2) 15% 22%
Loss before tax from continuing operations (12.7) (21.4) 41% 44%
Loss for the period including discontinued operations (21.6) (30.5) 29% 31%
Basic loss per share (p) (3.16) (4.60) 31% -
*2022 numbers have been restated to reflect changes to the ongoing continuing
business following the disposal of the tilapia business during the year.
** Constant exchange rate (CER) is the change year on year translating current
figures using last year's foreign exchange rates.
2023 2022 % AER % CER(**)
Adjusted Measures (£m unless otherwise stated) restated(*)
Gross profit from continuing operations 86.8 83.9 3% 4%
Gross profit % 51% 53% - -
Gross profit from continuing operations exc movements in fair value of 86.9 82.3 5% 6%
biological assets
Gross profit % 51% 52% - -
Adjusted EBITDA(1) from continuing operations 35.5 32.6 9% 11%
Adjusted EBITDA(1) margin % 21% 21% - -
Adjusted EBITDA(1) from continuing operations exc movements in fair value of 35.6 31.0 15% 16%
biological assets
Adjusted EBITDA(1) exc fair value movements margin % 21% 20% - -
Adjusted Operating Profit(2) from continuing operations 14.6 10.7 36% 41%
Net debt(3) (65.5) (73.7) 11% -
*2022 numbers have been restated to reflect changes to the ongoing continuing
business following the disposal of the tilapia business during the year.
** Constant exchange rate (CER) is the change year on year translating current
figures using last year's foreign exchange rates.
1 Adjusted EBITDA is EBITDA (earnings before interest, tax,
depreciation and amortisation and impairment) before exceptional and
acquisition-related items.
2 Adjusted Operating Profit is operating loss before exceptional and
acquisition-related items and amortisation of intangible assets excluding
development costs.
3 Net debt is cash and cash equivalents less loans, borrowings and
lease obligations.
Business area performance
We continued to manage costs across the Group very closely. Operating costs
from the continuing business increased by 2% to £45.2m (2022 restated:
£44.1m) with increased costs in Genetics and Advanced Nutrition driven in the
main by inflation offset by cost cuts in Health. Expensed R&D from
continuing operations decreased by 9% to £6.1m (2022 restated: £6.6m).
Adjusted EBITDA from continued operations increased by 9% to £35.5m (2022
restated: £32.6m) driven by increased performance in Health which offset
Genetics where we had significant investment in shrimp genetics as well as
lower fair value uplift and Advanced Nutrition.
Adjusted measures
We continue to use adjusted results as our primary measures of financial
performance. We believe that these adjusted measures enable a better
evaluation of our underlying performance. This is how the Board monitors the
progress of the Group.
We use growth at constant exchange rate metrics when considering our
performance, in which currency balances are retranslated at the same exchange
rates in use for the prior year to illustrate growth on a currency
like-for-like basis.
In line with many of our peers in the sector, we highlight expensed R&D on
the face of the income statement separate from operating expenses.
Furthermore, we report earnings before interest, tax, depreciation and
amortisation ("EBITDA") and EBITDA before exceptional and acquisition- related
items ("Adjusted EBITDA"). The activities of the Group's equity accounted
investees are closely aligned with the Group's principal activities, as these
arrangements were set up to exploit opportunities from the Intellectual
Property ("IP") held within the Group. As a result, to ensure that adjusted
performance measures are more meaningful, the Group's share of the results of
these entities is included within Adjusted EBITDA. We also report this
adjusted measure after depreciation and amortisation of capitalised
development costs ("Adjusted Operating Profit") as the Board considers this
reflects the result after taking account of the utilisation of the recently
expanded production capacity.
In addition, in line with the Salmon industry, we also report Gross profit and
AEBITDA excluding fair value uplift under IAS 41. Available liquidity, being
cash and undrawn facilities, is an important metric for management of the
business as it gives a measure of the available liquid funds and is also a key
financial covenant in the Group's main debt facilities.
Genetics
Despite forex headwinds impacting both NOK and ISK, Genetics delivered good
growth in revenue driven by sales of salmon eggs where volumes increased by
15% to 335 million eggs. Total revenues from continuing operations of £65.5m
(2022 restated: £57.4m) were up 14%, 20% in constant currency.
Egg sales in our biggest market, Norway, increased by 17% during the year,
with most of the demand being met by higher production volumes from our Salten
facility. We also saw increased sales to almost all other territories in the
year, resulting in an increase in revenue from salmon eggs of 19% to £45.6m
(2022: £38.3m).
In non-product-based revenue streams, revenues from harvested fish were aided
by increased salmon prices resulting in harvest income in the year of £11.1m
(2022: £8.5m). Royalties earned from use of our genetic IP fell in the year,
with sales down to £0.5m (2022: £0.8m). No further revenues are expected
from this revenue stream as the expected unwind of contracts is now complete.
Genetic Services delivered slightly lower revenues of £1.2m in the year
(2022: £1.3m), but revenues from this income stream are expected to increase
in future years as we build on the strength and depth of our recently expanded
genetics team and our IP in the business. Revenues from other products
totalled £7.4m (2022: £9.1m).
Gross profit from continuing operations reduced by 7% in 2023 to £30.6m (2022
restated: £32.8m) and gross margin fell to 47% (2022 restated: 57%). The
reduction in gross margin was due to a number of factors. We experienced
higher third-party production costs on our broodstock licence, inflation in
our own costs and non-capitalisation of shrimp development costs in the year
(£1.0m capitalised in 2022). Additionally, the fair value movement of bio
assets fell to a reduction of £0.1m in 2023 which is a combination of a
slowing in the growth of our biomass and lower eggs being incubated at the end
of the year, compared to an increase of £1.6m in 2022, as the overall value
of biological assets fell versus prior year.
The previously announced strategic review of our tilapia business was
completed in Q4 and as a result we sold the tilapia assets in a management
buy-out. Our Genetics Services team will continue to support the ongoing
development of the tilapia breeding programme on an arms-length basis. The
tilapia operation had revenues of £0.3m in the year (2022:£0.6m) and an
AEBITDA loss of £1.3m (2022: loss of £1.4m). We also booked exceptional
costs of £3.9m in the year (2022: £nil) relating to termination of the
business.
Our work to refine the shrimp genetics product line is ongoing and we have
lower commercial activities during the year. Prevailing conditions in the
shrimp markets have also affected this area of our business. Shrimp sales in
the year of £1.2m were behind last year (2022: £2.0m) and Adjusted EBITDA
losses of £3.6m were £2.0m worse than prior year, £1.0m of which, as noted
above, was due to capitalisation of development costs for the shrimp nucleus
in 2022 before it launched commercially.
R&D spend was £0.6m lower in the year (2023: £3.7m, 2022: £4.3m) and
operating costs were higher by £0.6m (2023: £11.2m, 2022: £ 10.6m) as the
business grew. R&D reduced due to good cost optimisation in this area.
R&D activities in this business area are focused on developing the traits
of growth, disease resistance and sea lice resistance by selecting the best
performing animals from each generation supported by cutting edge genetic
technologies. The search for markers for new traits that can be included in
the breeding programme continues.
The share of profits/losses from the equity accounted investees relates to the
joint venture with Salmar Genetics AS where we recorded a share of profit of
£0.03m in 2023 (2022: share of loss of £0.5m), and a share of losses of
£0.2m at Benchmark Genetics Thailand (2022: share of losses of £0.1m). Post
year- end, as part of consolidating the shrimp genetics business under Patrick
Waty, Genetics has continued to establish its facilities in Chile and with
overall AEBITDA losses of £2.9m and £0.1m invested in capex in these
facilities in 2023 (2022: £3.4m and 0.6mm). These facilities have potential
production capacity of 50 million eggs and is currently utilising capacity of
around 30 million eggs. During the year we sold 7 million eggs.
All these factors contributed to increased AEBITDA from continuing business of
£15.7m (2022 restated: £17.4m) and AEBITDA margin of 24% (2022 restated:
30%). AEBITDA from continuing business excluding fair value was the same as
prior year at £15.8m (2022 restated: £15.8m) with an AEBITDA margin of 24%
(2022 restated: 28%).
Advanced Nutrition
Throughout 2023, Advanced Nutrition delivered a resilient performance driven
by continued commercial and customer focus. Advanced Nutrition had a good
start to the year but at that stage we could already see weakening within the
shrimp markets. This continued throughout the year but we have delivered
strong results despite the market trends. Revenues in Advanced Nutrition
decreased by only 2% in the year (7% at CER) as our strong commercial focus
has allowed us to continue to strengthen our position and take increased
market share even as the market has softened.
In 2023 and 2022, 73% of our revenues derived from shrimp, with the balance
27% of derived from the Mediterranean sea bass and sea bream sector. By
product area, artemia revenue were £36.7m (2022: £37.4m) followed by diets
£32.6m (2022: £35.3m). health which covers our probiotic and environmental
pond management portfolio grew revenues by 13.6% to £9.2m (2022: £8.1m).
Gross profit of £43.8m (2022: £42.6m) showed an increase of 3% at AER but a
reduction of 1% at CER after the effect of the foreign exchange tailwinds.
However, good cost control and reducing logistics costs during the year along
with lower cost of goods for our Artemia products helped support the
resilience of the business. As a result we saw an increase in gross profit
margin up from 53% to 56%. This increase in gross profit was offset in part by
an increase in operating costs as we saw the full year effect of the
investment made in the business during 2022. There continued to be strong cost
control and where appropriate staff reductions throughout this year in light
of difficult market conditions. Operating costs grew to £23.4m (2022:
£21.5m). This led to Advanced Nutrition reporting AEBITDA of £18.4m (2022:
£19.0m) and a slight decrease in AEBITDA margin from 24% to 23%.
Within this business area, an important barrier to entry is the access to GSL
Artemia where we, through our relationship with the Great Salt Lakes
Cooperative have access to 44% of the annual harvest of Artemia from the Great
Salt Lakes.
Health
Health reported revenue of £25.5m (2022: £20.1m) largely reflecting
increased market traction for Ectosan®Vet and CleanTreat® which represented
of £17.2m of revenue (2022: £14.8m) of which £4.8m relates to revenue for
vessel-related costs (2022: £2.5m). Additionally, it was a good year for our
other sea lice treatment, Salmosan® Vet, which showed a resurgence of demand
in the year driven mainly by label changes which allow longer use in certain
territories and delivered revenue of £8.3m (2022: £5.4m).
Gross profit increased by £3.8m to £12.3m, driven by the increased sales
from of Ectosan®Vet and CleanTreat® combined with increased margins from
Salmosan® Vet. Gross margin increased to 48% (2022: 43%), due to increased
Ectosan®Vet and CleanTreat® sales.
During the year, the focus of this business area has been to drive demand for
Ectosan®Vet and CleanTreat® in Norway and also to lay the ground work for
moving the Cleantreat® treatments away from Benchmark leased and controlled
vessels, onto customer owned platforms. This will reduce the capital intensive
nature of the solution and ultimately reduce costs for the customer, making it
a more attractive solution to use for the treatment of sea lice. To date
capacity utilisation on the Cleantreat® vessels varied with treatment
seasonality which translated into utilisation of c.50% in each vessel during
FY23. We are reviewing different options to manage capacity and optimise
operations and cash flow as we transition towards fully integrated customer
owned systems on wellboats. This may include reducing the exposure to the
capital intensive setup we currently hold with two PSV's. With cash and cost
control being a very key focus for this business area, operating costs
decreased to £7.3m (2022: £8.1m) and research and development fell to £0.3m
(2022: £0.4m). Adjusted EBITDA for the business area was £4.8m (2022:
£0.1m). AEBITDA margin was 19% for 2023 (2022: 1%).
Within Health and Genetics, given the commonality of customers we adopted a
single sales and marketing team approach which has been in place during the
financial year. To further drive these efforts, Health and Genetics were
brought under common operational leadership during the year under Geir Olav
Melingen. We will continue to report these as separate segments to aid in
transparency of results.
Cost Inflation
As noted earlier, cost control remains of significant importance in Benchmark
and in the current inflationary environment becomes even more so. During the
year, we saw higher cost inflation in a number of areas, the most significant
of which related to salaries. Within Health we were able to mitigate this by
reducing the overall number of headcount and limiting discretionary spend.
Within Genetics and Advanced Nutrition, we have, within the constraints of
existing contracts, tried to increase prices and also limit discretionary
spend to mitigate. Within Advanced Nutrition, a number of roles were also
reorganised to make the operation leaner to best fit the current market
conditions.
Exceptional items
Items that are material because of their nature whose significance is
sufficient to warrant separate disclosure and identification within the
consolidated financial statements are referred to as exceptional items. The
separate reporting of exceptional items helps to provide an understanding of
the Group's underlying performance.
2023 2022
£mil £mil
Aborted acquisition related items 0.6 -
Exceptional restructuring costs 0.9 1.2
Costs associated with the Oslo listing 2.6 -
Cost in relation to disposals (0.2) (1.2)
Total exceptional items 3.9 (nil)
The above table excludes £3.9m of exceptionals included within discontinued
operations as mentioned earlier.
Exceptional expenses in 2023 were mainly driven by legal and professional
costs in relation to the dual listing on the Oslo exchange of and
consideration of uplisting to the Oslo Børs of £2.6m. Within Health and
Advanced Nutrition some restructuring occurred during the year, in Health to
move towards the integration of the operational leadership and within Advanced
Nutrition to adapt to the changes in the markets. This resulted in costs of
£0.9m (2022: £1.2m). The costs were offset by a credit of £0.2m (2022:
£1.2m) relating to additional contingent consideration received in the period
following the disposal of Improve International on 23 June 2020, actually cash
received was £1.25m related to this divestment.
Depreciation, amortisation and impairments
Depreciation and impairment of tangible assets including discontinued
operations and right of use assets was £18.7m (2022 restated: £19.9m). In
total, depreciation and impairment charges on right of use assets under IFRS
16 was £10.3m (2022 restated: £11.3m). The charge within discontinued
operations included above was £0.3m (2022: £0.2m). Amortisation and
impairment of intangible assets totalled £18.5m (2022: £19.2m). This
includes an impairment charge of £0.5m related to some intellectual property
within Health which is deemed no longer to be of value. We expect the
amortisation charge to start reducing from FY25 as some of the Advanced
Nutrition (INVE) assets will be fully amortised then.
Research and development
Expensed Total expensed and capitalised
2023 2023
£m Continuing business As % of sales 2022 As % of sales Continuing business As % of sales 2022 As % of sales
restated restated
Expensed R&D by business area
Genetics 3.7 6% 4.3 7% 3.7 6% 5.2 9%
Advanced Nutrition 2.1 3% 2.0 2% 2.1 3% 2.1 3%
Health 0.3 1% 0.4 2% 0.9 4% 1.0 5%
Total research and development 6.1 4% 6.7 4% 6.7 4% 8.3 5%
Expensed R&D activities decreased in the year by £0.5m with Genetics
having good cost optimisation in this area while continuing to focus on
improvements in the breeding nucleus. Health spending remained low due to
their significantly reduced R&D programmes. Genetics' research is focused
around continually developing new disease and parasitic resistant traits as
well as growth traits which we can breed into our products. Advanced
Nutrition's focus is on expanding our product portfolio and driving growth
through product improvements.
Other operating costs
As % of sales 2022 As % of sales
£m 2023 restated
Operating Expenses for continuing business by Business Area
Genetics 11.2 17% 10.6 18%
Advanced Nutrition 23.4 30% 21.5 27%
Health 7.3 29% 8.1 40%
Corporate (net) 3.3 3.9
Total operating expenses 45.2 27% 44.1 28%
Other operating costs within the continuing business increased from £44.1m in
2022 (restated) to £45.2m in 2023. The modest increase in costs reflects the
impact of cost inflation being mitigated by good cost control and limiting
discretionary spend.
Discontinued Operations
During the year we initiated a strategic review of our tilapia operations with
a view to understanding the timeline to cash generation within the area of our
Genetics business. As a consequence of this review we divested the business
via a management buy-out in the fourth quarter of the financial year.
Net finance costs
2022
£m 2023 restated
Interest Income (0.6) (0.3)
Foreign Exchange gains (0.3) (2.8)
Interest on bond and bank debt 8.4 6.2
Amortisation of deferred financing fees 0.5 1.9
Penalty for early settlement of the bond - 1.6
Movements in hedging instruments (2.2) 7.0
Finance lease interest 1.6 1.6
Total net finance expenses 7.4 15.2
The Group incurred net finance costs of £7.4m during the year (2022 restated:
£15.2m). Included within this was interest charged on the Group's
interest-bearing debt facilities of £8.4m (2022: £6.2m), the higher interest
cost was due to higher utilisation of the RCF facility during the year and
also higher interest coupon on the bond. In addition, a further £0.5m was
charged on amortisation of the deferred finance costs (2022: £1.9m). Net
foreign exchange gains of £0.3m (2022 restated: net gain of £2.8m) arose due
to the movement in exchange rates on intercompany loans and external debt.
Movements on the hedging instruments associated with the Group's NOK bond debt
resulted in gains of £2.2m (2022: loss of £7.0m).
Statutory loss before tax
The loss before tax from continuing operations for the year at £12.7m is
lower than the prior year (2022 restated: loss of £21.4m). This was a result
of the positive trading result offset by higher exceptional items and lower
finance costs due to changes in fair value of in-effective portion of cash
flow hedges slightly offset by unfavourable foreign exchange movements.
Taxation
There was a tax charge on the loss for the year of £3.4m (2022: £7.3m),
mainly due to overseas tax charges in Genetics and Advanced Nutrition in
territories where no loss relief is available, partially offset by deferred
tax credits on intangible assets mainly arising on consolidation from
acquisitions.
Other Comprehensive Income
In addition to the loss for the year of £21.6m, there was a significant
movement of £23.0m in OCI resulting from movements in the foreign exchange
and hedging reserves. The forex loss of £23.5m was driven by USD and NOK
impacting the retranslation of foreign currency denominated subsidiary balance
sheets into GBP offset by amounts designated as net investment hedges,
together with long term internal loans not expected to be repaid in the
foreseeable future which are treated like equity with the movements going
directly to reserves. These were offset by £0.5m credit into the hedge
reserve from hedge accounting on cashflow hedges.
Transfer and cancellation of share premium
During 2023, we obtained approval via the AGM to cancel part of the share
premium account and transfer it to retained earnings. This amounted to
£394.2m. This has allowed the business to increase its distributable reserves
and serves as a step towards the goal of being a cash generative group, able
to issue dividends in line with its dividend policy.
Reported loss for the year
The loss for the year from the continuing business was £16.1m (2022 restated:
loss of £28.7m). The total loss from continuing activities and discontinued
operations was £21.6m (2022: £30.5m).
Loss per share
Basic loss and diluted loss per share were both 3.16p (2022: loss per share
4.60p). The movement year on year is due to the movement in the result as well
as the increase in the weighted average number of shares in issue of 33.7m.
Dividends
No dividends have been paid or proposed in either 2023 or 2022 and the Board
is not recommending a final dividend in respect of the year ended 30 September
2023.
Biological assets
A feature of the Group's net assets is its investment in biological assets,
which under IAS 41 are stated at fair value. At 30 September 2023, the
carrying value of biological assets was £46.0m (2022: £46.7m). This decrease
is due principally to the reduction in eggs available for sale in FY24
compared to FY23, as demand for our eggs was higher at the start of FY23 while
there were supply issues in the market which did not affect Benchmark. This
has normalised during the year. The fair value movement on biological assets
included in cost of sales for the year was a reduction of £0.1m (2022: uplift
of £1.6m).
Intangibles
Additions to intangibles were £0.8m (2022: £1.9m) with the main area of
investment being capitalised development costs which in the year decreased by
£1.1m to £0.6m (2022: £1.7m). R&D costs related to products that are
close to commercial launch have to be capitalised when they meet the
requirements set out under IAS 38. In this financial year, the main
development project capitalised was Salmosan Vet (£0.6m).
Capital expenditure
During 2023, to manage cash, we curtailed the investment incurred and focussed
on purely business critical areas. The Group incurred tangible fixed asset
additions of £6.0m (2022: £10.8m) broken down as follows:
· Health: £0.7m (2022: £2.6m)
· Genetics: £3.4m (2022: £5.6m)
· Nutrition: £1.9m (2022: £2.6m)
Within Health, there was an increase in the provision to demobilise the
Cleantreat® units from the current vessels of £0.4m and additional equipment
for the existing Cleantreat® units of £0.3m. Capex associated with our
Genetics business was £3.4m where we finished the building of new tanks at
Salten to support ramping up to the 150 million egg capacity at that facility
(£1.4m) and we continue to invest in our production footprint in Iceland and
Salten. 2023 saw minimal investment in our growth initiatives in Chile and
shrimp as we believe they have been sufficiently invested. In Advanced
Nutrition we continued to invest in the two manufacturing facilities to
support growth and operational efficiency.
Cashflow, liquidity and net debt
2023 2022
Movement in net debt £m £m
Net debt at 30 September 2022/2021 (73.7) (80.9)
Cash generated from operations excluding working capital and taxes paid 29.6 30.3
Investment in working capital (1.1) (12.0)
Capital expenditure (6.8) (12.7)
Other disposal activities 0.2 (0.2)
Foreign exchange on cash and debt 4.3 10.5
Interest and tax (17.1) (17.0)
Proceeds from previous year disposals of subsidiaries 1.3 1.5
Acquisition of subsidiaries net of cash/debt acquired (0.2) -
Investment in associates (0.6) (0.4)
Acquisition of non controlling interest (8.0) -
Additions to/modifications of leases (IFRS 16) (3.7) (11.5)
Shares issued 10.9 20.2
Other non-cash movements (0.6) (1.5)
Net debt at 30 September 2023/2022 (65.5) (73.7)
Cash flow
With improved trading in the business, we saw strong cash generated from
operations of £29.6m (2022: £30.3m). During 2023 with significant focus on
cash conservation, we restricted the investment in working capital to £1.1m
versus an outflow last year £12.0m. Interest and taxes were in line with last
year. Capital expenditure, both intangible and tangible, showed a significant
decrease of £5.9m to £6.8m (2022: £12.7m) as we continue to moderate our
capex.
Working capital
Working capital has reduced slightly in the period driven by a number of
factors. We can see the impact of foreign exchange on the balance sheet as
noted above in the other comprehensive income section and this impacted the
working capital balances at 30 September 2023, but our investment in working
capital was more moderate this year as can be seen in the cash flow.
We noted earlier the decrease in biological assets within the genetics areas.
Other Inventories fell in Advanced Nutrition as we had less GSL Artemia in
inventory than previous years.
In Health, we had transferred the CleanTreat® equipment into inventory in
2022 but we had lower levels of inventory of Salmosan® Vet than 2022.
Trade debtors and creditors, of course, increased as a result of increased
sales but trade debtors decreased as a percentage of sales from 20% to 16% in
the year. Trade payables were 20% higher than last year as expected from
higher level of costs both from activity levels and from cost inflation.
A significant amount of cash is tied up with the working capital of the group
and focus will continue to be on releasing that investment in the years to
come.
Refinancing and borrowing facilities
The Group has a senior unsecured green bond issue of NOK 750 million, with an
expected maturity date of 27 September 2025. The bond has a coupon of three
months NIBOR* + 6.5% p.a. with quarterly interest payments. The Group also had
a USD 15m revolving credit facility ("RCF") which was due to mature in
December 2022 and had £4m drawn at 30 September 2022. During the year, this
RCF was refinanced by a new £20m RCF on 21 November 2022 with a June 2025
maturity. The interest rate on the facility is between 2.5% and 3.25% above
compound interest rate depending on leverage. At 30 September 2023, there was
£7.75m drawn on this facility (2022: £4.0m).
There are other borrowing facilities held within Benchmark Genetics Salten AS
which were originally put in place to fund the building of the Salten salmon
eggs facility. On 1 November 2022 the term loan facility outstanding balance
and the overdraft facility provided by Nordea were refinanced into one
facility totalling NOK179.5m with a maturity date of January 2028. The margin
on the new facility is 2.5%. In addition, a working capital facility of NOK
20.0m (renewal annually in March) is in place for use solely by Benchmark
Genetics Salten AS. This facility is undrawn (2022: undrawn). Two additional
ten-year term loans of NOK 25,000,000 and NOK 30,000,000 respectively provided
by Innovasjon Norge in 2018. These loans currently have a flat interest rate
of 5.95% per annum.
Cash and total debt
Net debt
£m 2023 2022
Cash 36.5 36.4
NOK 750m bond (57.6) (62.0)
Other borrowings (24.5) (21.8)
Lease liabilities (19.9) (26.3)
Net debt (65.5) (73.7)
The RCF combined with the year-end cash balance of £36.5m (2022: £36.4m)
means the Group had total liquidity of £48.8m (2022: £45.8m). This, while
utilising tight cost and cash control, is expected by the Directors to provide
the Group with sufficient liquidity to fund the investment and working capital
required to crystalise the growth opportunities which are part of the
strategic priorities of the Group and provide adequate headroom.
Equity raise and Oslo Euronext Growth Listing
In December 2022, £10.8m net proceeds were raised through a placing to
provide the Company with sufficient free float to establish a listing on Oslo
Euronext Growth. The listing was completed on 15 December 2022 and we have
remained dual listed since that time. During 2023, the Board considered an
uplisting to Oslo Børs but ultimately through shareholder consultation, the
decision was made to remain dual listed on Euronext Growth and AIM. The
proceeds of this equity raise facilitated us in having sufficient available
cash to purchase the minority interest in our Icelandic operation.
Covenants
Banking covenants for the NOK bond and RCF exist in relation to liquidity and
an 'equity ratio'. Liquidity, defined as 'freely available and unrestricted
cash and cash equivalents, including any undrawn amounts under the RCF', must
always exceed the minimum liquidity value, set at £10m. Available liquidity
at 30 September 2023 is £48.8m (2022: £45.8m). The equity ratio, defined as
'the ratio of Book Equity to Total Assets' must always exceed 40%. The equity
ratio at 30 September 2023 was 60% (2022: 61%). In addition, an equity to
asset ratio covenant exists for the Benchmark Genetics Salten AS debt with a
target threshold of 40%, this equity to asset ratio was 60.0% at 30 September
2023 (2022: 51.3%).
Acquisition of Iceland minority Interest
In December 2014 Benchmark acquired an 89.48% interest in Stofnfiskur,
subsequently rebranding it Benchmark Genetics Iceland. Since the acquisition,
the business has grown substantially, benefitting from Benchmark's leading
market position, investment and knowledge transfer within the Group. In
February 2023, we acquired the remaining 10.52% minority interest in Benchmark
Genetics Iceland for a consideration of €9m. This acquisition is
strategically important as Benchmark Genetics Iceland is core to the Company's
ability to supply highly specialist, biosecure salmon eggs year-round to
salmon producers in c.25 countries around the world. Benchmark Genetics
Iceland represents 50% of the Group's salmon egg capacity.
Going concern
As at 30 September 2023 the Group had net assets of £282.6m (2022: £323.3m),
including cash of £36.5m (2022: £36.4m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £21.6m (2022: £30.5m).
As at 30 September 2023 the Company had net assets of £363.2m (2022:
£346.6), including cash of £0.3m (2022: £3.2m) as set out on the Company
Balance Sheet. The Company made a loss for the year of £4.2m (2022: £16.5m).
As noted in the Strategic Report, the business has performed steadily during
the year, showing resilience to some tough market conditions towards the end
of the year. The Directors have reviewed forecasts and cash flow projections
for a period of at least 12 months including downside sensitivity assumptions
in relation to trading performance across the Group to assess the impact on
the Group's trading and cash flow forecasts and on the forecast compliance
with the covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan® Vet and CleanTreat® offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduction in short-term treatment capacity. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivities on sales growth in revenues and pressure on pricing on CIS
artemia in Advanced Nutrition. Mitigating measures within the control of
management have been identified should they be required in response to these
sensitivities, including reductions in areas of discretionary spend, tight
control over new hires, deferral of capital projects and temporary hold on
R&D for non-imminent products.
The refinancing exercise which commenced in FY22 was completed at the start of
FY23, so that adequate finance facilities are in place, and with financial
instruments in place to fix interest rates and opportunities available to
mitigate globally high inflation rates, the Group continues to show resilience
against current global economic pressures. The Directors are therefore
confident that even under all of the above sensitivity analysis, the Group has
sufficient liquidity and resources throughout the period under review whilst
still maintaining adequate headroom against the borrowing covenants. They
therefore remain confident that the Group has adequate resources to continue
to meet its liabilities as and when they fall due within the period of 12
months from the date of approval of these financial statements. Based on their
assessment, the Directors believe it remains appropriate to prepare the
financial statements on a going concern basis.
Consolidated Income Statement
for the year ended 30 September 2023
2022
2023 Restated*
£000 £000
Revenue 169,476 157,707
Cost of sales (82,726) (73,777)
Gross profit 86,750 83,930
Research and development costs (6,069) (6,634)
Other operating costs (45,157) (44,095)
Share of (loss)/profit of equity-accounted investees, net of tax (32) (595)
Adjusted EBITDA² 35,492 32,606
Exceptional - restructuring/acquisition and disposal related items 4 (3,904) 16
EBITDA¹ 31,588 32,622
Depreciation and impairment (18,409) (19,692)
Amortisation and impairment (18,495) (19,161)
Operating loss (5,316) (6,231)
Finance cost 3 (15,048) (19,893)
Finance income 3 7,670 4,741
Loss before taxation (12,694) (21,383)
Tax on loss (3,365) (7,268)
Loss from continuing operations (16,059) (28,651)
Discontinued operations
Loss from discontinued operations, net of tax 5 (5,505) (1,800)
(21,564) (30,451)
Loss for the year attributable to:
- Owners of the parent (23,146) (32,087)
- Non-controlling interest 1,582 1,636
(21,564) (30,451)
Earnings per share
Basic loss per share (pence) 6 (3.16) (4.60)
Diluted loss per share (pence) 6 (3.16) (4.60)
Earnings per share - continuing operations
Basic loss per share (pence) 6 (2.41) (4.34)
Diluted loss per share (pence) 6 (2.41) (4.34)
£000 £000
Adjusted EBITDA from continuing operations 35,492 32,606
Adjusted EBITDA from discontinued operations (1,254) (1,425)
Total Adjusted EBITDA 34,238 31,181
1. EBITDA - earnings before interest, tax, depreciation, amortisation
and impairment.
2. Adjusted EBITDA - EBITDA before exceptional and acquisition-related
items.
* 2022 numbers have been restated to reflect certain operations of the
Group that have been classified as discontinued operations during the year in
line with IFRS 5
Consolidated Statement of Comprehensive Income
for the year ended 30 September 2023
2023 2022
£000 £000
Loss for the year (21,564) (30,451)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences (23,475) 47,606
Cash flow hedges - changes in fair value (2,123) 2,627
Cash flow hedges - reclassified to profit or loss 2,623 2,546
Total comprehensive income for the period (44,539) 22,328
Total comprehensive income for the period attributable to:
- Owners of the parent (45,404) 20,326
- Non-controlling interest 865 2,002
(44,539) 22,328
Total comprehensive income for the period attributable to owners of the
parent:
- Continuing operations (39,777) 21,509
- Discontinued operations* (5,627) (1,183)
(45,404) 20,326
* Total comprehensive income for the period relating to discontinued
operations for FY23 includes the loss of £5,505,000 (2022: £1,800,000) and
foreign exchange loss of £122,000 (2022: gain of £617,000).
Consolidated Balance Sheet
as at 30 September 2023
2023 2022
Notes £000 £000
Assets
Property, plant and equipment 7 73,411 81,900
Right-of-use assets 8 19,804 27,034
Intangible assets 9 206,077 245,264
Equity-accounted investees 3,558 3,113
Other investments 14 15
Biological and agricultural assets 11 18,406 20,878
Non-current assets 321,270 378,204
Inventories 25,269 29,813
Biological and agricultural assets 11 27,586 25,780
Trade and other receivables 10 59,795 56,377
Cash and cash equivalents 36,525 36,399
149,175 148,369
Assets held for sale 850 -
Current assets 150,025 148,369
Total assets 471,295 526,573
Liabilities
Trade and other payables 13 (47,329) (44,324)
Loans and borrowings 14 (20,045) (17,091)
Corporation tax liability (6,422) (10,211)
Provisions (1,280) (1,631)
Current liabilities (75,076) (73,257)
Loans and borrowings 14 (81,954) (93,045)
Other payables 13 (6,842) (8,996)
Deferred tax (24,106) (27,990)
Provisions (700) -
Non-current liabilities (113,602) (130,031)
Total liabilities (188,678) (203,288)
Net assets 282,617 323,285
Issued capital and reserves attributable to owners of the parent
Share capital 739 704
Additional paid-in capital 37,428 420,824
Capital redemption reserve 5 5
Retained earnings 183,489 (185,136)
Hedging reserve (203) (703)
Foreign exchange reserve 54,947 77,705
Equity attributable to owners of the parent 276,405 313,399
Non-controlling interest 6,212 9,886
Total equity and reserves 282,617 323,285
The financial statements were approved and authorised for issue by the Board
of Directors on 29 November 2023 and were signed on its behalf by:
Septima Maguire
Chief Financial Officer
Company number: 04115910
Consolidated Statement of Changes in Equity
for the year ended 30 September 2023
Share capital Additional paid-in share capital Other reserves Hedging reserve Retained earnings Total attributable to equity holders of parent Non-controlling interest Total equity
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2021 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income for the year
(Loss)/profit for the year - - - - (32,087) (32,087) 1,636 (30,451)
Other comprehensive income - - 47,240 5,173 - 52,413 366 52,779
Total comprehensive income for the year - - 47,240 5,173 (32,087) 20,326 2,002 22,328
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 1,182 1,182 - 1,182
Total contributions by and distributions to owners 34 20,142 - - 1,182 21,358 - 21,358
Changes in ownership
Acquisition of NCI - - - - - - - -
Total changes in ownership interests - - - - - - - -
Total transactions with owners of the Company 34 20,142 - - 1,182 21,358 - 21,358
As at 30 September 2022 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income for the year
(Loss)/profit for the period - - - - (23,146) (23,146) 1,582 (21,564)
Other comprehensive income - - (22,758) 500 - (22,258) (717) (22,975)
Total comprehensive income for the year - - (22,758) 500 (23,146) (45,404) 865 (44,539)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (2,146) - - - (2,146) - (2,146)
Cancellation of part of share premium account - (394,235) - - 394,235 - - -
Share-based payment - - - - 1,006 1,006 - 1,006
Total contributions by and distributions to owners 35 (383,396) - - 395,241 11,880 - 11,880
Changes in ownership
Acquisition of NCI - - - - (3,470) (3,470) (4,359) (8,009)
Total changes in ownership interests - - - - (3,470) (3,470) (4,359) (8,009)
Total transactions with owners of the Company 35 (383,396) - - 391,771 8,410 (4,539) (8,009)
As at 30 September 2023 739 37,428 54,952 (203) 183,489 276,405 6,212 282,617
Consolidated Statement of Cash Flows
for the year ended 30 September 2023
2023 2022
Notes £000 £000
Cash flows from operating activities
Loss for the year (21,564) (30,451)
Adjustments for:
Depreciation and impairment of property, plant and equipment 8,453 8,602
Depreciation and impairment of right-of-use assets 10,260 11,293
Other adjustments for non-cash items - (276)
Amortisation and impairment of intangible fixed assets 18,495 19,161
Profit on sale of property, plant and equipment (121) (43)
Loss on sale of discontinued operation 3,774 -
Finance income (2,802) (319)
Finance costs 10,535 18,437
Increase in fair value of contingent consideration receivable - (1,203)
Share of loss of equity-accounted investees, net of tax 32 595
Foreign exchange gains (1,814) (3,985)
Share-based payment expense 1,005 1,182
Tax expense 3,365 7,274
Increase in trade and other receivables (6,570) (8,511)
Decrease/(increase) in inventories 2,877 (5,406)
Increase in biological and agricultural assets (1,659) (6,099)
Increase in trade and other payables 3,909 6,948
Increase in provisions 386 1,058
28,561 18,257
Income taxes paid (8,556) (7,447)
Net cash flows generated from operating activities 20,005 10,810
Investing activities
Acquisition of subsidiaries (48) -
Purchase of investments in associates (558) (378)
Receipts from disposal of subsidiaries 1,250 1,544
Purchases of property, plant and equipment (5,953) (10,808)
Purchase of intangibles (196) (205)
Capitalised research and development costs (632) (1,708)
Proceeds from sale of fixed assets 227 220
Cash receipts from swap contracts 11 -
Interest received 627 119
Net cash flows used in investing activities (5,272) (11,216)
Financing activities
Proceeds of share issues 13,020 20,737
Share-issue costs recognised through equity (2,146) (562)
Acquisition of minority interests in subsidiaries (8,009) -
Proceeds from bank or other borrowings 21,847 67,939
Repayment of bank or other borrowings (18,470) (74,874)
Interest and finance charges paid (9,131) (9,629)
Repayments of lease liabilities (9,438) (10,533)
Net cash used in financing activities (12,327) (6,922)
Net increase/(decrease) in cash and cash equivalents 2,406 (7,328)
Cash and cash equivalents at beginning of year 36,399 39,460
Effect of movements in exchange rate (2,280) 4,267
Cash and cash equivalents at end of year 36,525 36,399
1. Basis of preparation
These audited results have been prepared on the basis of the accounting
policies which are to be set out in Benchmark Holdings Plc's annual report and
financial statements for the year ended 30 September 2023. Those policies have
been consistently applied to all the years presented unless otherwise stated.
These Group and parent company financial statements were prepared and approved
by the Directors in accordance with (i) UK-adopted International Accounting
Standards and (ii) IFRS adopted pursuant to Regulation (EC) No. 1606/2002 as
it applied in the European Union ("Adopted IFRS"). While the financial
information included in this preliminary statement has been prepared on the
basis of the requirements of IFRSs in issue, this statement does not itself
contain sufficient information to comply with IFRS.
The financial information set out above does not constitute the company's
statutory accounts for the years ended 30 September 2023 or 2022 but is
derived from those accounts. Statutory accounts for 2022 have been delivered
to the registrar of companies, and those for 2023 will be delivered in due
course. The auditor has reported on those accounts. The auditor's reports for
2023 and for 2002 were both (i) unqualified and (ii) did not contain a
statement under section 498(2) or (3) of the Companies Act 2006.
The financial statements are prepared on the historical cost basis except that
the following assets and liabilities are stated at their fair value: certain
financial assets and financial liabilities (including contingent consideration
receivable and derivatives) and biological assets measured at fair value.
Non-current assets and disposal groups held for sale are stated at the lower
of previous carrying amount and fair value less costs to sell.
Going concern
As at 30 September 2023 the Group had net assets of £282.6m (2022: £323.3m),
including cash of £36.5m (2022: £36.4m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £21.6m (2022: £30.5m).
As noted in the Strategic Report, the business has performed steadily during
the year, showing resilience to some tough market conditions towards the end
of the year. The Directors have reviewed forecasts and cash flow projections
for a period of at least 12 months including downside sensitivity assumptions
in relation to trading performance across the Group to assess the impact on
the Group's trading and cash flow forecasts and on the forecast compliance
with the covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduction in short-term treatment capacity. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivities on sales growth in revenues and pressure on pricing on CIS
artemia in Advanced Nutrition. Mitigating measures within the control of
management have been identified should they be required in response to these
sensitivities, including reductions in areas of discretionary spend, tight
control over new hires, deferral of capital projects and temporary hold on
R&D for non-imminent
products.
The refinancing exercise which commenced in FY22 was completed at the start of
FY23, so that adequate finance facilities are in place, and with financial
instruments in place to fix interest rates and opportunities available to
mitigate globally high inflation rates, the Group continues to show resilience
against current global economic pressures. The Directors are therefore
confident that even under all of the above sensitivity analysis, the Group has
sufficient liquidity and resources throughout the period under review whilst
still maintaining adequate headroom against the borrowing covenants. They
therefore remain confident that the Group has adequate resources to continue
to meet its liabilities as and when they fall due within the period of 12
months from the date of approval of these financial statements. Based on their
assessment, the Directors believe it remains appropriate to prepare the
financial statements on a going concern basis.
2. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
- Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.
- Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
- Health -the segment focuses on providing health products to the
global aquaculture market.
In order to reconcile the segmental analysis to the Consolidated Income
Statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy was
applied consistently throughout the current and prior period.
Genetics Advanced Nutrition Health Corporate Inter-segment Total
£000 £000 £000 £000 sales £000
Year ended 30 September 2023 £000
Revenue 65,791 78,503 25,514 5,747 (5,811) 169,744
Cost of sales (35,876) (34,704) (13,173) - 54 (83,699)
Gross profit / (loss) 29,915 43,799 12,341 5,747 (5,757) 86,045
Research and development costs (3,778) (2,071) (279) - - (6,128)
Operating costs (11,696) (23,354) (7,290) (9,064) 5,757 (45,647)
Share of profit of equity-accounted investees, net of tax (32) - - - - (32)
Adjusted EBITDA 14,409 18,374 4,772 (3,317) - 34,238
Exceptional - restructuring/acquisition and disposal related items (3,913) (920) (509) (2,475) - (7,817)
EBITDA 10,496 17,454 4,263 (5,792) - 26,421
Depreciation and impairment (4,703) (2,437) (11,559) (14) - (18,713)
Amortisation and impairment (1,894) (14,269) (2,329) (3) - (18,495)
Operating profit / (loss) 3,899 748 (9,625) (5,809) - (10,787)
Finance cost (15,082)
Finance income 7,670
Loss before tax (18,199)
Genetics Advanced Nutrition Health Corporate Inter-segment Total
£000 £000 £000 £000 sales £000
Year ended 30 September 2022 £000
Revenue 58,008 80,286 20,135 5,120 (5,272) 158,277
Cost of sales (25,971) (37,733) (11,544) 4 95 (75,149)
Gross profit / (loss) 32,037 42,553 8,591 5,124 (5,177) 83,128
Research and development costs (4,329) (1,990) (372) - - (6,691)
Operating costs (11,133) (21,546) (8,111) (9,048) 5,177 (44,661)
Share of profit of equity-accounted investees, net of tax (595) - - - - (595)
Adjusted EBITDA 15,980 19,017 108 (3,924) - 31,181
Exceptional - restructuring/acquisition and disposal related items - (220) 18 218 - 16
EBITDA 15,980 18,797 126 (3,706) - 31,197
Depreciation and impairment (5,322) (2,236) (12,251) (88) - (19,897)
Amortisation and impairment (1,695) (15,000) (2,463) (3) - (19,161)
Operating profit / (loss) 8,963 1,561 (14,588) (3,797) - (7,861)
Finance cost (20,057)
Finance income 4,741
Loss before tax (23,177)
Non-current assets by location of assets
2023 2022
£000 £000
Belgium 144,344 173,136
Norway 74,541 83,752
UK 29,690 42,373
Iceland 37,631 39,448
Rest of Europe 1,017 953
Rest of world 34,047 38,543
321,270 378,204
3. Net finance costs
2023 2022
Continuing operations £000 Restated
£000
Interest received on bank deposits 627 319
Foreign exchange gains on financing activities 158 4,422
Foreign exchange gains on operating activities 4,709 -
Cash flow hedges - ineffective portion of changes in fair value 2,176 -
Finance income 7,670 4,741
Leases (interest portion) (1,620) (1,580)
Cash flow hedges - re-classified from OCI - (2,546)
Cash flow hedges - in-effective portion of changes in fair value - (4,475)
Foreign exchange losses on operating activities (4,547) (1,620)
Interest expense on financial liabilities measured at amortised cost (8,881) (9,672)
Finance costs (15,048) (19,893)
Net finance costs recognised in profit or loss (7,378) (15,152)
4. Exceptional items - restructuring, acquisition and disposal related
items
Items that are material because of their nature, non-recurring or whose
significance is sufficient to warrant separate disclosure and identification
within the consolidated financial statements are referred to as exceptional
items. The separate reporting of exceptional items helps to provide an
understanding of the Group's underlying performance.
2023 2022
£000 £000
Acquisition related items 652 -
Exceptional restructuring costs 3,470 1,229
Disposal related items (218) (1,245)
Total exceptional items 3,904 (16)
Acquisition related items comprise fees incurred in the year in connection
with an aborted acquisition.
Exceptional costs include: £2,598,000 (2022: £843,000) of legal and
professional costs in relation to preparing for listing the Group on the Oslo
stock exchange, and £872,000 (2022: £276,000) relating to restructuring
costs.
Disposal related items include a credit of £235,000 (2022: £1,203,000) in
relation to additional contingent consideration received and receivable from
disposals in previous years (£294,000 relating to the disposal of Aquaculture
UK on 7 February 2020, and £909,000 relating to the disposal of Improve
International Limited and its subsidiaries on 23 June 2020) together with
legal fees, lease costs and disposal items (net of proceeds received)
totalling £17,000 relating to additional costs and disposals proceeds
relating to disposals that occurred in 2020.
5. Discontinued operations
During the year, the group divested its tilapia business for consideration of
USD 1 in a management buy out. Consequently, these operations have been
classified as discontinued in the current year with a corresponding
restatement of the consolidated income statement and OCI for the year ended 30
September 2022 to reflect these changes.
Summary of restatement of FY22 results as reported in FY22 financial
statements
Continuing operations Discontinued operations
Revenue Adjusted EBITDA Loss from continuing operations Loss from discontinued operations
£000 £000 £000 £000
As stated in financial year 2022 financial statements 158,277 31,181 (30,451) -
Reclassified in financial year 2023 (570) 1,425 1,800 (1,800)
As stated in financial year 2023 financial statements 157,707 32,606 (28,651) (1,800)
2023 Restated
£000 2022
£000
Revenue 268 570
Cost of sales (973) (1,372)
Gross profit (705) (802)
Research and development costs (59) (57)
Other operating costs (490) (566)
Adjusted EBITDA (1,254) (1,425)
Exceptional loss on disposal (3,913) -
EBITDA (5,167) (1,425)
Depreciation and impairment (304) (205)
Operating loss / Loss before taxation (5,471) (1,630)
Net finance costs (34) (164)
Loss before taxation (5,505) (1,794)
Tax on loss - (6)
Loss from discontinued operations (5,505) (1,800)
Exceptional items within discontinued operations
2022
2023 Restated
£000 £000
Loss on disposal of trade and assets 3,774 -
Other costs relating to disposals 139 -
Total exceptional loss on disposal 3,913 -
Cash flows from discontinued operations
2023 2022
£000 £000
Net cash flow from operating activities (1,609) (1,312)
Net cash flow from investing activities (27) (341)
Net cash flow from financing activities (106) 77
Net cash flow from discontinued operations (1,742) (1,576)
Results from discontinued operations by segment
The results from discontinued operations relate solely to the Genetics
operating segment.
Impact on the Group Consolidated Income Statement for the year ended 30
September 2023
2023 2023 2023
Continuing Discontinued Total
£000 £000 £000
Revenue 169,476 268 169,744
Cost of sales (82,726) (973) (83,699)
Gross profit 86,750 (705) 86,045
Research and development costs (6,069) (59) (6,128)
Other operating costs (45,157) (490) (45,647)
Share of profit of equity-accounted investees, net of tax (32) - (32)
Adjusted EBITDA 35,492 (1,254) 34,238
Exceptional - restructuring, acquisition and disposal related items (3,904) (3,913) (7,817)
EBITDA 31,588 (5,167) 26,421
Depreciation and impairment (18,409) (304) (18,713)
Amortisation and impairment (18,495) - (18,495)
Operating loss (5,316) (5,471) (10,787)
Net finance costs (7,378) (34) (7,412)
Loss before taxation (12,694) (5,505) (18,199)
Tax on loss (3,365) - (3,365)
Loss after tax for the financial period (16,059) (5,505) (21,564)
Impact on the Group Consolidated Income Statement for the year ended 30
September 2022
2022 2022 2022
Continuing Restated Discontinued Total
£000 Restated Restated
£000 £000
Revenue 157,707 570 158,277
Cost of sales (73,777) (1,372) (75,149)
Gross profit 83,930 (802) 83,128
Research and development costs (6,634) (57) (6,691)
Other operating costs (44,095) (566) (44,661)
Share of profit of equity-accounted investees, net of tax (595) - (595)
Adjusted EBITDA 32,606 (1,425) 31,181
Exceptional - restructuring, acquisition and disposal related items 16 - 16
EBITDA 32,622 (1,425) 31,197
Depreciation and impairment (19,692) (205) (19,897)
Amortisation and impairment (19,161) - (19,161)
Operating loss (6,231) (1,630) (7,861)
Net finance costs (15,152) (164) (15,316)
Loss before taxation (21,383) (1,794) (23,177)
Tax on loss (7,268) (6) (7,274)
Loss after tax for the financial period (28,651) (1,800) (30,451)
Effects of business disposals on the financial position of the Group
On 30 September, the tilapia businesses of a Group's subsidiary was disposed
of for consideration of USD 1. The assets sold are
highlighted in the table below.
Tilapia
£000
Assets
Property, plant and equipment (including Right of use assets) 738
Intangible assets 3,036
Net assets and liabilities 3,774
Total consideration -
Consideration received in cash -
Cash and cash equivalents disposed of -
Net cash inflow/(outflow) -
6. Loss per share
Basic loss per share is calculated by dividing the profit or loss attributable
to ordinary equity holders of the Company by the
weighted average number of ordinary shares in issue during the period.
2023 2022
Continuing Discontinued Total Continuing Discontinued Total
Loss attributable to equity holders of the parent (£000) (17,641) (5,505) (23,146) (30,287) (1,800) (32,087)
Weighted average number of shares in issue (thousands) 731,935 698,233
Basic loss per share (pence) (2.41) (0.75) (3.16) (4.34) (0.26) (4.60)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value based on the monetary value of the
subscription rights attached to outstanding share options and warrants.
A total of 8,948,132 (2022: 6,240,304) potential ordinary shares have not been
included within the calculation of statutory diluted loss per share for the
year as they are anti-dilutive and reduce the loss per share. However, these
potential ordinary shares could dilute earnings per share in the future. The
diluted and basic loss per share are the same for both continuing and
discontinued.
7. Property, plant and equipment
Group
Freehold Land and Buildings Assets in the course of construction Long-Term Leasehold Property Plant and Machinery Office Equipment and Fixtures Total
£000 £000 Improvements £000 £000 £000
£000
Cost
Balance at 1 October 2021 63,027 1,807 6,421 32,893 2,751 106,899
Additions 4,025 1,616 283 4,546 338 10,808
Increase/(decrease) through transfers from assets in the course of 251 (1,275) - 995 29 -
construction
Exchange differences 1,924 116 432 2,377 146 4,995
Transfer to inventory - - - (1,514) - (1,514)
Disposals (224) - - (131) (126) (481)
Disposals through sale of subsidiary - - - - - -
Balance at 30 September 2022 69,003 2,264 7,136 39,166 3,138 120,707
Balance at 1 October 2022 69,003 2,264 7,136 39,166 3,138 120,707
Additions 2,164 560 28 2,662 539 5,953
On acquisition - - - 315 - 315
Reclassification 56 (106) - 50 - -
Increase/(decrease) through transfers from
assets in the course of construction 877 (1,556) - 679 - -
Exchange differences (4,446) (53) (344) (1,670) (328) (6,841)
Transfer to assets held for sale (1,392) - - - - (1,392)
Transfer from inventory - - - 94 - 94
Balance at 30 September 2023 66,181 1,109 5,245 39,175 3,291 115,001
Accumulated depreciation
Balance at 1 October 2022 7,829 - 4,723 14,806 761 28,119
Depreciation charge for the year 2,387 - 197 5,411 607 8,602
Exchange differences 792 - 256 1,200 141 2,389
Disposals (84) - - (102) (117) (303)
Balance at 30 September 2022 10,924 - 5,176 21,315 1,392 38,807
Balance at 1 October 2022 10,924 - 5,176 21,315 1,392 38,807
Depreciation charge for the year 2,266 - 79 5,513 595 8,453
Transfer to assets held for sale (542) - - - - (542)
Exchange differences (908) - (189) (810) (214) (2,121)
Disposals (81) - (1,575) (1,323) (28) (3,007)
Balance at 30 September 2023 11,659 - 3,491 24,695 1,745 41,590
Net book value
At 30 September 2023 54,522 1,109 1,754 14,480 1,546 73,411
At 30 September 2022 58,079 2,264 1,960 17,851 1,746 81,900
At 1 October 2021 55,198 1,807 1,698 18,087 1,990 78,780
8. Leases
Group
2023 2022
Right-of-use-assets £000 £000
Leasehold property 9,213 9,389
Plant and machinery 10,585 17,582
Office equipment and fixtures 6 63
19,804 27,034
Lease liabilities 2023 2022
£000 £000
Current 11,567 11,522
Non-current 8,293 14,765
19,860 26,287
Depreciation charge of right-of-use assets 2023 2022
£000 £000
Leasehold property 1,210 1,383
Plant and machinery 9,038 9,176
Office equipment and fixtures 12 72
10,260 10,631
Additional information 2021 2020
£000 £000
Additions to right-of-use assets 2,120 497
Modifications to right-of-use assets 1,697 10,884
Impairment of leasehold property right-of-use asset - 664
Interest expense 1,654 1,744
Expense relating to short-term leases 237 152
Expense relating to leases of low-value leases 20 151
Total cash outflow for leases 9,438 10,533
Benchmark Animal Health Limited modified the existing leases for two PSV
vessels, the FS Aquarius and the FS Pegasus to extend the lease term only.
These two assets constitute £8,405,000 of the net book value and £9,374,000
of the lease liability at the year end.
9. Intangible assets
Group
Websites Goodwill Patents and Trademarks Intellectual Property Customer Lists Contracts Licences Genetics Development costs Total
£000 £000 £000 £000 £000 £000 £000 £000 £000 £000
Cost or valuation
Balance at 1 October 2021 319 140,055 338 133,201 5,271 6,602 34,479 22,636 27,579 370,480
Additions - externally acquired 94 - 111 - - - - - - 205
Additions - internally developed - - - - - - - - 1,708 1,708
Exchange differences 34 24,619 3 27,206 1,107 (27) 5,841 599 1,935 61,317
Balance at 30 September 2022 447 164,674 452 160,407 6,378 6,575 40,320 23,235 31,222 433,710
Balance at 1 October 2022 447 164,674 452 160,407 6,378 6,575 40,320 23,235 31,222 433,710
Additions - on acquisition - - - - - - - - - -
Additions - externally acquired 80 1 115 - - - - - - 196
Additions - internally developed - - - - - - - - 632 632
Disposals - (3,036) (21) - - - (150) - - (3,207)
Reclassification to assets held for resale - - - - - - - - - -
Exchange differences (15) (13,682) (1) (13,737) (559) (70) (3,186) (1,267) (982) (33,499)
Balance at 30 September 2023 512 147,957 545 146,670 5,819 6,505 36,984 21,968 30,872 397,832
Accumulated amortisation and impairment
Balance at 1 October 2021 67 41,358 133 73,541 1,166 6,210 13,077 4,111 1,777 141,440
Amortisation charge for the period 67 - 70 13,574 215 102 2,027 636 2,165 18,856
Impairment - - - 305 - - - - - 305
Exchange differences 9 8,592 3 16,966 275 (19) 1,839 139 41 27,845
Balance at 30 September 2022 143 49,950 206 104,386 1,656 6,293 16,943 4,886 3,983 188,446
Balance at 1 October 2022 143 49,950 206 104,386 1,656 6,293 16,943 4,886 3,983 188,446
Amortisation charge for the period 85 - 91 12,605 222 94 1,818 606 2,437 17,958
Impairment - 1 - 61 - - 476 - - 538
Disposals - - (21) - - - (150) - - (171)
Exchange differences (4) (4,484) (2) (8,868) (143) (52) (1,177) (253) (33) (15,016)
Balance at 30 September 2023 224 45,467 274 108,184 1,735 6,335 17,910 5,239 6,387 191,755
Net book value
At 30 September 2023 288 102,490 271 38,486 4,084 170 19,074 16,729 24,485 206,077
At 30 September 2022 304 114,724 246 56,021 4,722 282 23,377 18,349 27,239 245,264
At 1 October 2021 252 98,697 205 59,660 4,105 392 21,402 18,525 25,802 229,040
The table below provides further detail of intangibles and their remaining
amortisation period.
NBV 2023 NBV 2022 Remaining life
Description Category £000 £000 2023
Acquisition of INVE in 2015
Goodwill Goodwill 79,909 87,585 -
Harvesting rights Licences 19,029 22,449 12
Product technology Intellectual property - 446 -
Product rights Intellectual property 24,880 39,390 2
Brand names Intellectual property 10,945 12,976 12
In-process R&D Intellectual property 535 847 2
Customer relationships Customer lists 4,085 4,723 18
Total relating to acquisition of INVE 139,383 168,416 -
Acquisition of Salmobreed AS (Now part of Benchmark Genetics Norway AS) in
2014
Goodwill Goodwill 6,063 6,523 -
Genetic material and breeding nuclei Genetics 8,926 9,911 31
Total relating to acquisition of Salmobreed AS 14,989 16,434 -
Acquisition of Stofnfiskur( Now Benchmark Genetics Iceland) in
2014
Goodwill Goodwill 11,999 12,467 -
Genetic material and breeding nuclei Genetics 7,598 8,147 31
Total relating to acquisition of Stofnfiskur 19,597 20,614 -
Acquisition of Akvaforsk Genetics Center AS (Now part of
Benchmark Genetics Norway AS) in 2015
Goodwill Goodwill 4,520 7,348 -
Licences Licences - 292 -
Contracts Contracts 170 282 2
Total relating to acquisition of Akvaforsk Genetics Center AS 4,690 7,922 -
Capitalised development costs
8
Not yet ready
for use
Ectosan®Vet/CleanTreat® Development costs 14,048 15,840
Live food alternative diets Development costs 3,879 4,115
SPR Shrimp Development costs 5,453 6,686 8
Total capitalised development costs 23,380 26,641
Other purchased material intangible assets Intellectual Property 1,408 1,497 16
Total relating to other purchased intangible assets 1,408 1,497
Other individually immaterial goodwill and intangibles 2,630 3,740
Total net book value at 30 September 206,077 245,264
10. Impairment testing of goodwill and other intangible assets
The Group tests goodwill and other intangibles not yet ready for use annually
for impairment, or more frequently if there are indications that goodwill or
the other intangible assets might be impaired. Goodwill acquired in a business
combination is allocated, at acquisition, to the cash generating units (CGUs)
that are expected to benefit from the business combination. The only
intangible assets not yet ready for use are generally the capitalised
development costs on internally developed products. The development costs
included in the table below represents only those that are not yet ready for
use.
Due to the interdependence of the operations within each of the business areas
and the way in which they are managed, management have determined the CGUs are
the business areas themselves - Health, Genetics and Advanced Nutrition. These
are the smallest groups of assets that independently generate cashflows and
whose cashflows are largely independent of those generated by other assets.
Goodwill and capitalised development costs arise across the Group, and are
allocated specifically against the CGUs as follows:
Genetics Advanced Nutrition
2023 2023 Total
£000 £000 2023
£000
Benchmark Genetics AS 6,062 - 6,062
Benchmark Genetics Iceland HF (Previously Stofnfiskur HF) 11,999 - 11,999
Akvaforsk Genetic Center* 4,520 - 4,520
INVE Aquaculture Group - 79,909 79,909
Goodwill 22,581 79,909 102,490
Development costs - 3,879 3,879
* Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).
Advanced
Genetics Nutrition Total
2022 2022 2022
£000 £000 £000
Benchmark Genetics AS 6,522 - 6,522
Benchmark Genetics Iceland HF (Previously Stofnfiskur HF) 12,467 - 12,467
Akvaforsk Genetic Center* 8,150 - 8,150
INVE Aquaculture Group - 87,585 87,585
Goodwill 27,139 87,585 114,724
Development costs - 4,115 4,115
* Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).
The recoverable amounts of the above CGUs have been determined from
value-in-use calculations. These calculations used Board approved cash flow
projections from five-year business plans based on actual operating results
and current forecasts. These forecasts were then extrapolated into perpetuity
taking account of specific terminal growth rates for future cash flows, using
individual business operating margins based on past experience and future
expectations in light of anticipated economic and market conditions. The
pre-tax cash flows that these projections produced were discounted at pre-tax
discount rates based on the Group's beta adjusted cost of capital, further
adjusted to reflect management's assessment of specific risks related to the
markets and other factors pertaining to each CGU. Forecasts also include any
costs in relation to the Group's climate change strategy and climate change
factors have been considered when setting the long-term growth rates.
The values assigned to the key assumptions represent management's assessment
of future trends in the relevant industries and have been based on historical
data from both external and internal sources.
Genetics
The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 15.7% (2022: 14.7%). CAGR of revenue of 9% (2022:
15%) is implied by the five-year plan and a long-term growth rate of 2.5%
(2022: 2.5%) has been used to extrapolate the terminal year cashflow into
perpetuity.
Having conducted a sensitivity analysis of key assumptions, no reasonably
possible changes that would result in the elimination
of all headroom were identified.
Advanced Nutrition
The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 16.4% (2022: 15.6%). CAGR of revenue of 12% (2022:
10%) is implied by the five-year plan and a long-term growth rate of 3.5%
(2022: 3.5%) has been used to extrapolate the terminal year cashflow into
perpetuity. Market analysis reports predict long-term growth rates of c.5.0%,
and the health benefits of shrimp are still very much in evidence. Management
believes that a long-term growth rate of 3.5% represents both a prudent and
consistent approach for the CGU.
Sensitivity analysis has been performed on the key assumptions. Reducing the
forecast growth rates for less mature parts of the CGU within Health and Diets
products did not result in elimination of headroom. However, the forecasts
growth rates for the CGU include an assumption around the ongoing recovery in
global shrimp markets, and if that recovery is slower than the forecasts
anticipate, due to factors such as continued reduced end market demand for
Shrimp, to the extent that the CAGR of revenue implied over the five-year plan
falls to 9%, this would result in a potential impairment.
The sensitivity to movements in the terminal growth rate and discount rate
were also assessed, and a reduction in terminal growth rate from 3.5% to 1.5%,
or an increase in the discount rate from 16.4% to 18.4%, either of which are
considered to be reasonably possible, would reduce the headroom on the
Advanced Nutrition CGU of £31.6m to nil. Should the growth rate reduce or
discount rate increase further than this, then an impairment would be likely.
Health
The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 17.4% (2022: 16.4%). An assumed CAGR of revenue of
23% (2022: 27%) in the five-year plan reflects the importance of the
successful commercial ramp- up of the business area's new sea lice treatment
in the forecast period. A long-term growth rate of 0.0% (2022: 0.0%) has been
used to extrapolate the terminal year cashflow into perpetuity. The prudent
assumption in the long-term growth rate is intended to reflect that the
business area's new sea lice treatment is the principal source of cash
generation, and only benefits from patent protection against generic
competitors for a finite period of time.
The valuation of the Health cash generating unit indicates sufficient headroom
such that a reasonably possible change to key assumptions is unlikely to
result in an impairment in related development costs.
11. Biological assets
Book value of biological assets recognised at fair value
Group 2023 2022
£000 £000
Salmon eggs 10,631 14,037
Salmon broodstock 33,411 30,501
Salmon milt 796 606
Lumpfish fingerlings 757 1,090
Shrimp 397 424
Total biological assets 30 September 45,992 46,658
Analysed as
Current 27,586 25,780
Non-current 18,406 20,878
Total biological assets 30 September 45,992 46,658
Change in book value of biological assets
2023 2022
£000 £000
Biological assets 1 October Increase 46,658 38,365
Increase from production 42,393 48,067
Reduction due to sales (40,583) (45,535)
Other movements in biological assets 1,810 4,532
Foreign exchange movement before fair value adjustment (1,562) 1,704
Change in fair value through income statement (103) 1,595
Foreign exchange impact on fair value adjustment (811) 462
Biological assets 30 September 45,992 46,658
Assumptions used for determining fair value of biological assets
IAS 41 requires that biological assets are accounted for at the estimated fair
value net of selling and harvesting costs. Fair value is measured in
accordance with IFRS 13 and is categorised into levels in the fair value
hierarchy.
The fair value inputs for salmon eggs are categorised as level 2. The
calculation of the fair value of the salmon eggs is based upon the current
seasonally adjusted selling prices for salmon eggs less transport and
incubation costs and taking account of the market capacity. The valuation also
takes account of the mortality rates of the eggs and expected life as sourced
from internally generated data.
The fair value inputs for salmon broodstock are categorised as level 3. The
broodstock contain generations of genetic improvements and cannot be valued
purely on the market weight of salmon. The Group does not sell its broodstock
commercially so there is no observable input in this respect. Therefore, the
calculation of the estimated fair value of salmon broodstock is primarily
based upon its main harvest output being salmon eggs, which are priced upon
the current seasonally adjusted selling prices for the Group's salmon eggs.
These prices are reduced for harvesting costs, freight costs, incubation costs
and market capacity to arrive at the net value of broodstock. The valuation
also reflects the internally generated data to arrive at the biomass.
This includes the weight of the broodstock, the yield that each kilogram of
fish will produce and mortality rates. The fish take four years to reach
maturity, and the age and biomass of the fish is taken into account in the
fair value. Finally, the valuation takes account of future expected sales
volumes.
Change in book value of salmon broodstock
2023 2022
£000 £000
Biological assets 1 October 30,501 26,700
Increase from production 25,494 28,720
Transfer to salmon eggs following harvesting (22,677) (26,509)
Foreign exchange movement before fair value adjustment (1,199) 1,326
Change in fair value through income statement 1,853 (31)
Foreign exchange impact on fair value adjustment (561) 295
Biological assets 30 September 33,411 30,501
Significant unobservable inputs used in the valuation of salmon broodstock
2023 2022
Number of eggs valued in broodstock (m units) 250 222
Average selling price per egg (GBP) 0.131 0.135
Future costs per egg (GBP) (0.016) (0.021)
The fair value inputs for lumpfish fingerlings and shrimp are categorised as
level 2. The calculation of the fair value of lumpfish fingerlings and shrimp
is valued on current selling prices less transport costs. Internally generated
data is used to incorporate mortality rates and the weight of the biomass.
The fair value inputs for lumpfish fingerlings and shrimp are categorised as
level 2. The calculation of the fair value of lumpfish fingerlings and shrimp
is valued on current selling prices less transport costs. Internally generated
data is used to incorporate mortality rates and the weight of the biomass.
The fair value inputs for salmon milt are categorised as level 3. Where we
have identified individual salmon carrying particular traits or disease
resistance, semen (milt) can be extracted and deep-frozen using
cryopreservation techniques (the process of freezing biological material at
extreme temperatures in liquid nitrogen). The calculation of the fair value of
milt is based on production and freezing costs and, where appropriate, an
uplift to recognise the additional selling price that can be achieved from
eggs fertilised by premium quality milt.
There is a presumption that fair value can be measured reliably for a
biological asset. However, we sometimes face a situation where alternative
estimates of fair value are determined to be clearly unreliable (for example,
where we establish a new broodstock farm in a new territory). In such a case,
that biological asset shall be measured at its cost less any accumulated
impairment losses. In the year this applied to £2,150,000 of broodstock in
Chile. As at 30 September the gross carrying amount was £5,186,000 (2022:
£4,704,000) and the accumulated impairment losses were £3,036,000 (2022:
£2,735,000).The valuation models by their nature are based upon uncertain
assumptions on sales prices, market capacity, weight, mortality rates, yields
and assessment of the discounts to reflect the stages of maturity. The Group
has a degree of expertise in these assumptions but these assumptions are
subject to change. Relatively small changes in assumptions would have a
significant impact on the valuation. A 1% increase/decrease in the assumed
selling price per egg would increase/decrease the fair value of salmon
broodstock and eggs by £440,000. A 10% increase/decrease in the biomass of
salmon broodstock and the quantity of salmon eggs valued would
increase/decrease the fair value of those biological assets by £4,404,000.
The Group is exposed to financial risks arising from changes in the market
value of the salmon eggs, lumpfish fingerlings and shrimp broodstock that it
sells. The Group does not anticipate that prices will decline significantly in
the foreseeable future and, therefore, has not entered into derivative or
other contracts to manage the risk of a decline in the price of its products.
The Group reviews its outlook for salmon eggs, lumpfish fingerlings and shrimp
broodstock prices regularly in considering the need for active financial risk
management.
Risk management strategy related to aquaculture activity
The Group is exposed to the following risks relating to its aquaculture
activities. These risks and management's strategies to mitigate them are
described below:
Regulatory and environmental risks
The nature of certain of the Group's operating activities exposes us to
certain significant risks to the environment, such as incidents associated
with releases of chemicals or hazardous substances when conducting our
operations, which could result in liability, fines, risk to our product
permissions and reputational damage. There is a risk that natural disasters
could lead to damage to infrastructure, loss of resources, products or
containment of hazardous substances. Our business activities could be
disrupted if we do not respond, or are perceived not to respond, in an
appropriate manner to any major crisis or if we are not able to restore or
replace critical operational capacity.
In mitigation we have implemented standards and requirements which govern key
risk management activities such as inspection, maintenance, testing, business
continuity and crisis response.
Biological risks
The Group is exposed to the risk of disease within the Group's own operations
and disease in the market resulting in possible border closures. In
mitigation, the Group:
· Operates the highest levels of biosecurity.
· Holds genetic stock at multiple sites and increasingly sources from its
own land-based salmon breeding facilities.
· Operates containment zones which mitigates the risk of border closures
affecting its ability to import or export.
· Has placed increased focus on insuring its biological stock.
Outputs and quantities held
Total output of aquaculture activity in the year was:
2023 2022
Salmon eggs 334.7m units 291.1m units
Lumpfish fingerlings 1.5m units 2.0m units
Total quantities held at 30 September were:
2023 2022
Salmon eggs 85.6m units 103.9m units
Salmon broodstock 1,517 tonnes 1,737 tonnes
Lumpfish fingerlings 0.4m units 0.7m units
12. Trade and other receivables
2023 2022
Group £000 £000
Trade receivables 27,460 31,218
Less: provision for impairment of trade receivables (2,612) (2,748)
Trade receivables - net 24,848 28,470
Total financial assets other than cash and cash equivalents measured at 24,848 28,470
amortised cost
Other receivables - contingent consideration - 887
Total financial assets other than cash and cash equivalents classified as
measured at fair value through
profit and loss - 887
Prepayments 18,081 14,989
Other receivables 16,866 12,031
Total trade and other receivables 59,795 56,377
Other receivables relate to the following items: VAT recoverable £4,353,000
(2022: £4,386,000), research and development expenditure tax credits and
similar items £157,000 (2022: £154,000), the right to receive an agreed
proportion of a key supplier's harvest* £10,173,000 (2022: £5,249,200),
accrued income of £1,177,000 (2022: £1,377,000) and other amounts receivable
of £1,006,000 (2022: £865,000).
*A financial liability of £10,173,000 (2022: £5,249,200) is recognised
(within trade payables) for the amount invoiced and remaining outstanding at
the year-end in relation to the Group's contractual obligation to pay for a
specified share of the harvest of a supplier, regardless of delivery and
without recourse to the supplier. As at 30 September, as the Group has not
taken physical delivery of the harvested product and as the Group does not
control the harvested product, an 'other receivable' of £10,173,000 (2022:
£5,249,200) has been recorded in relation to the Group's right to receive the
product in the future.
The financial asset at fair value through profit and loss related to
contingent consideration outstanding from the disposal of Improve
International Limited in FY20. This related to deferred cash consideration
dependent on the delivery of certain future revenues in the financial year
ended 30 September 2022 and the fair value was derived from the likely
receivable amount based on expectations of performance against the targets.
The amount recovered in the financial year ended 30 September 2023 was not
materially different to management's estimate.
The fair values of trade and other receivables measured at amortised cost are
not materially different to their carrying values. As at 30 September 2023
trade receivables of £6,313,000 (2022: £5,943,000) were past due but not
impaired. They relate to customers with no default history. The ageing
analysis of these receivables is as follows:
2023 2022
£000 £000
Up to 3 months overdue 5,480 5,761
3 to 6 months overdue 833 218
6 to 12 months overdue - (36)
6,313 5,943
Movements on the Group provision for impairment of trade receivables are as
follows:
2023 2023
£000 £000
At 1 October 2,748 2,493
Provided during the year 696 281
Unused provisions reversed (600) (180)
Provisions used during the year (32) -
Foreign exchange movements (200) 154
At 30 September 2,612 2,748
The movement on the provision for impaired receivables has been included in
the operating costs line in the Consolidated Income Statement.
Other classes of financial assets included within trade and other receivables
do not contain impaired assets.
13. Trade and other payables
2023 2022
Group £000 £000
Trade payables 26,657 22,149
Other payables 2,213 1,127
Accruals 16,257 17,636
Other payables - tax and social security payments 2,957 3,799
Financial liabilities, excluding loans and borrowings, classified as financial 48,084 44,711
liabilities measured at amortised cost
Financial contracts - hedging instrument 5,683 8,012
Financial liabilities, excluding loans and borrowings, classified as financial 5,683 8,012
liabilities at fair value through profit or loss
Deferred income 404 597
Total trade and other payables 54,171 53,320
Less: non-current portion of other payables (6,842) (8,996)
Current portion 47,329 44,324
Book values approximate to fair value at 30 September 2023 and 2022.
Of the financial contracts £6,155,000 (2022: £8,387,000) relates to a NOKUSD
floating to fixed cross-currency interest rate swap (CCS) and a NOK interest
rate swap (IRS), both of which were entered to fully match the timing and
tenor of the underlying new senior unsecured floating rate listed bond issue
of NOK 750m.
The floating-to-fixed NOK IRS (notional NOK 300m) is designated a cash flow
hedge where any changes in the fair value of the swap will be taken directly
to equity within the hedging reserve and recycled to profit or loss as the
bond impacts the profit or loss.
The NOKUSD CCS (notional NOK450m) has been separated into two synthetic swaps;
the first is a floating-to-fixed NOKGBP interest rate swap, being a cash flow
hedge of the foreign exchange and interest rate risk on NOK denominated debt.
The fair value of this synthetic swap is posted to the hedging reserve in
equity. The second synthetic swap is a fixed-to-fixed GBPUSD swap designated
as a net investment hedge in the USD net assets in the consolidated accounts
of Benchmark Holdings plc. The fair value of this leg is posted to the foreign
exchange translation reserve in equity.
14. Loans and borrowings
Group
2023 2022
£000 £000
Non-Current
2025 750m NOK Loan notes 57,604 61,976
Bank borrowings 16,799 17,226
Unamortised debt issue costs (742) (922)
Lease liabilities 8,293 14,765
81,954 93,045
Current
Bank borrowings 9,320 5,569
Unamortised debt issue costs (842) -
Lease liabilities 11,567 11,522
20,045 17,091
Total loans and borrowings 101,999 110,136
At 30 September 2023 the fair value of the unsecured floating rate listed
green bond of NOK 750m was NOK 791m.
On 21 November 2022, the Group refinanced its USD15m RCF with a secured GBP20m
RCF provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this
facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk free reference or IBOR rates
depending on which currency is drawn.
Benchmark Genetics Salten AS had the following loans (which are ring-fenced
debt without recourse to the remainder of the Group) at 30 September 2023:
· Term loan with a balance of NOK 171.9m provided by Nordea Bank
Norge Abp. The loan is a five-year term loan maturing no later than January
2028 at an interest rate of 2.5% above three-month NIBOR. This loan refinanced
the previous term loan from the same bank when the outstanding balance of NOK
162 million was repaid in February 2023.
· NOK 20.0m 12-month working capital facility provided by Nordea
Bank Norge Abp. This was undrawn at 30 September 2023 (2022: undrawn).
· Term loan with a balance of NOK 35.5m (2022: NOK 40.1m) provided
by Innovasjon Norge. The loan is a 12-and-a-half-year term loan maturing in
March 2031. The interest rate on this loan at 30 September 2023 was 7.45%. The
interest rate on this loan is variable.
· A new term loan with a balance of NOK 10.0m provided by
Innovasjon Norge. The loan is a 15-year term loan maturing in July 2038. The
interest rate on this loan at 30 September 2023 was 7.45%. The interest rate
on this loan is variable.
· NOK 21.75m loan provided by Salten Stamfisk AS (the minority
shareholder). The loan attracts interest at 2.5% above three month NIBOR and
is repayable on maturity of the Nordea term loan above.
The lease liabilities are secured on the assets to which they relate.
The currency profile of the Group's loans and borrowings is as follows:
2023 2022
£000 £000
Sterling 16,680 19,697
Norwegian Krone 76,730 81,634
Thai Baht 464 954
Euro 614 272
US Dollar 6,460 6,888
Icelandic Krone 585 545
Other 466 146
101,999 110,136
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FR BKLBLXFLBFBV